L35,36,37 CKD Pharmacology, Therapeutics, Labs

Descripción

PHCY310 Test sobre L35,36,37 CKD Pharmacology, Therapeutics, Labs, creado por Mer Scott el 16/04/2019.
Mer Scott
Test por Mer Scott, actualizado hace más de 1 año
Mer Scott
Creado por Mer Scott hace más de 5 años
9
0

Resumen del Recurso

Pregunta 1

Pregunta
Three determinants of renin release: 1. Decreased [blank_start]Na+ concentration[blank_end] sensed by kidney 2. Decreased BP or renal [blank_start]blood flow[blank_end] 3. [blank_start]Beta 2[blank_end] receptor activation
Respuesta
  • Na+ concentration
  • blood flow
  • Beta 2

Pregunta 2

Pregunta
Angiotensin causes profound vasoconstriction and aldosterone release.
Respuesta
  • True
  • False

Pregunta 3

Pregunta
Both ACEIs and ARBS will decrease systemic vascular resistance and increase renal perfusion.
Respuesta
  • True
  • False

Pregunta 4

Pregunta
Diuretics for CKD: 1. Loop diuretics inhibit the activity of the Na-K-2Cl symporter in the [blank_start]thick ascending loop of Henle[blank_end]. Therefore maximum effect is ~[blank_start]20-25[blank_end]%. 2. Thiazide diuretics inhibit the activity of the Na-Cl symporter in the [blank_start]distal tubule[blank_end]. Maximum effect is ~[blank_start]5[blank_end]%. 3. K-sparing diuretics inhibit the activity of epithelial Na+ channels in the [blank_start]late distal tubule and collecting duct[blank_end]. Maximum effect is ~[blank_start]2[blank_end]%. 4. Aldosterone antagonists competitively inhibit the binding of [blank_start]aldosterone[blank_end] to the mineralocorticoid receptor. The only class of diuretics that do not enter the tubule cell from the apical ([blank_start]tubular[blank_end]) side, and instead from the basolateral ([blank_start]blood[blank_end]) side.
Respuesta
  • thick ascending loop of Henle
  • 20-25
  • distal tubule
  • 5
  • late distal tubule and collecting duct
  • 2
  • aldosterone
  • blood
  • tubular

Pregunta 5

Pregunta
Classification of CKD: • Normal/ CKD 1: GFR >90 mL/min • Mild/ CKD 2: GFR [blank_start]60-90[blank_end] mL/min • Moderate/ CKD 3: GFR [blank_start]30-60[blank_end] mL/min • Severe/ CKD 4: GFR [blank_start]15-30[blank_end] mL/min • End-stage/ CKD 5: GFR <15 mL/min
Respuesta
  • 60-90
  • 30-60
  • 15-30

Pregunta 6

Pregunta
Non-pharmacological treatment of CKD entails dietary sodium restriction, and protein restriction if GFR < 30mL/min.
Respuesta
  • True
  • False

Pregunta 7

Pregunta
When using ACEIs and ARBs in CKD the target is a reduction in urine [blank_start]albumin[blank_end] of 30-50%. Starting can [blank_start]reduce[blank_end] GFR; start at a [blank_start]low[blank_end] dose and titrate the dose slowly to effect. Other Important side effects to consider: • [blank_start]Hyper[blank_end]kalaemia • [blank_start]Acute[blank_end] renal impairment • Dry cough (fairly [blank_start]common[blank_end]) • Angioedema ([blank_start]rare[blank_end], but serious)
Respuesta
  • albumin
  • reduce
  • low
  • Hyper
  • Acute
  • common
  • rare

Pregunta 8

Pregunta
Methods of estimating renal function: 1. Creatinine-based methods (CLcr, eGFR) • Collection of 24 hour urine samples ([blank_start]creatinine[blank_end] clearance) • Cockcroft-Gault [blank_start]Equatoin[blank_end] (an estimate of creatinine clearance) • MDRD • CKD-EPI All these are reported by the lab as “[blank_start]eGFR[blank_end]”. 2. Cystatin C clearance 3. Clearance of a [blank_start]xenobiotic[blank_end]: Inulin (NOT insulin), 51Cr EDTA (radioisotope)
Respuesta
  • creatinine
  • Equation
  • eGFR
  • xenobiotic

Pregunta 9

Pregunta
Creatinine is freely filtered by the glomerulus and so its clearance lets us estimate GFR.
Respuesta
  • True
  • False

Pregunta 10

Pregunta
Cockcroft & Gault equation: CLcr = ( (140 - [blank_start]Age[blank_end]) x [blank_start]ideal body weight[blank_end] x K* ) / [blank_start]serum creatinine[blank_end] * K = 1.23 for males, 1.04 for females
Respuesta
  • age
  • ideal body weight
  • serum creatinine

Pregunta 11

Pregunta
All creatinine-based methods; • Are poor predictors of GFR if malnourished or low [blank_start]muscle[blank_end] mass • Over-estimate GFR in the elderly, [blank_start]obese[blank_end] (using total body weight), severe or end-stage renal disease • Not for <[blank_start]18[blank_end] years old • Unreliable when renal function [blank_start]changing[blank_end] rapidly (acute renal failure) • Drugs [blank_start]inhibiting[blank_end] tubular secretion can raise creatinine conc (e.g. probenecid, trimethoprim, spironolactone)
Respuesta
  • muscle
  • 18
  • changing
  • obese
  • inhibiting

Pregunta 12

Pregunta
In CKD, K+ secretion is [blank_start]reduced[blank_end] resulting in accumulation. Concentrations above [blank_start]5.5-6[blank_end]mmol/L become symptomatic. Hyperkalaemia is more likely to be observed in CKD 4 or 5, and is exacerbated by [blank_start]ACE-I, ARBs[blank_end] and K-sparing diuretics.
Respuesta
  • reduced
  • 5.5-6
  • ACE-I, ARBs

Pregunta 13

Pregunta
Match the ranges. - Creatinine (plasma): Adult male: 50-[blank_start]110[blank_end] µmol/L, Adult female: 45-[blank_start]90[blank_end] µmol/L - Urea (plasma): Adults: [blank_start]3.2-7.7[blank_end] mmol/L - Sodium (plasma) [blank_start]135-145[blank_end] mmol/L - Osmolality (plasma) 280-[blank_start]300[blank_end] mmol/kg - Osmolality (urine) 300-[blank_start]1200[blank_end] mmol/kg
Respuesta
  • 110
  • 90
  • 3.2-7.7
  • 135-145
  • 300
  • 1200
Mostrar resumen completo Ocultar resumen completo

Similar

Capas de la Tierra
Diego Santos
Test Sobre los ríos de España
Grupo Máquinas
Márketing (Conceptos básicos)
Lina Hernandez13
Comunicación Gerencial
lvmendoza9
FARMACOLOGÍA CARDIOVASCULAR
may.856
Ciclo Menstrual
Juno Enyell's M
Emergencias y primeros auxilios
renevivero23
GoConQr. EJEMPLOS...
Ulises Yo
Los tipos de Emprendedores Existentes
Laura -
ALFAyOMEGA [A– / Z–]...
Ulises Yo